Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence - Arjun Balar

Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence

Presentation from the 2017 Annual LUGPA meeting in Chicago, IL

(Length of presentation: 28 min)

Arjun Balar, MD discusses the need for cancer immunotherapy, a biologically-driven form of therapy where the body’s immune system is used to fight cancer. In the past, Cisplatin/Methotrexate was the therapy of choice in treating bladder cancer since it had the highest response rates as single agents. Now, immunotherapy for bladder cancer broadens the scope of treatment with the addition of 5 new drugs in the second-line setting.   The pros and cons of each drug including administration, dosing schedules and disease monitoring are discussed as well as other factors including when to use immuno versus chemo therapies and the safety and toxicity of each therapy.

Biography:
Arjun Balar, MD is the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center. Dr. Balar's research focuses on bladder cancer and immunotherapy—treatments that harness the body’s own immune system to fight the cancer—as well as molecularly-targeted therapy. He has extensive experience treating prostate, testicular, and kidney cancers and leads a team of medical oncologists, nurse practitioners, social workers, and other care providers who are dedicated to treating people who have genitourinary cancers.